Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development

Sylvia Faict, MD, Josephine Muller, PhD, Kim De Veirman, PhD, Ken Maes, Elke De Bruyne, PhD, Rik Schots, Jo Caers, MD PhD, Karin Vanderkerken, PhD, Eline Menu, PhD

Blood (2018) 132 (Supplement 1): 4484.

https://doi.org/10.1182/blood-2018-99-112428

Published: 2018

Journal Articles

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Attaya Suvannasankha, MD, Colin Crean, BS, Isaac Carrera Ochoa, G David Roodman, MD PhD, John Chirgwin, PhD

Blood (2018) 132 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2018-99-115680

Published: 2018

Journal Articles

TBK1/Ikkε Inhibitor Amlx Blocks Multiple Myeloma Cell Growth in Vitro and In Vivo

Quanhong Sun, PhD, Peng Zhang, PhDMD, Juraj Adamik, PhD, Konstantinos Lontos, MD, Valentina Marchica, MS, Nicola Giuliani, MD PhD, Rebecca W. Silbermann, MD, G. David Roodman, MD PhD, Deborah Lynn Galson, PhD

Blood (2018) 132 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2018-99-119677

Published: 2018

Journal Articles

Decreased Skeletal Health Negatively Impacts Quality of Life of People with Hemophilia

Galen Goldscheitter, BS, BA, Susan Lattimore, Jason A Taylor, MD PhD

Blood (2018) 132 (Supplement 1): 1207.

https://doi.org/10.1182/blood-2018-99-113086

Published: 2018

Journal Articles

Uninvolved Immunoglobulin Suppression Determined By "Hevylite" ASSAY. Strongly Predicts Evolution of Smoldering Myeloma (SMM) to Symptomatic Multiple Myeloma (MM)

Paraskevi Papaioannou, MD, Annita Ioanna Gkioka, MD, Kallirroi Tsalimalma, MD, Aspasia Koudouna, MD, Anastasia Kopsaftopoulou, MD, Konstantina Chamoulkou, MD, Ioannis Grafakos, MD, Aikaterini Bitsani, MD, Theodoros Iliakis, MD, Maria Dimou, MD PhD, Nikolitsa Kafassi, MD, Petros Sfikakis, MD PhD, Panayiotis Panayiotidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD

Blood (2018) 132 (Supplement 1): 5584.

https://doi.org/10.1182/blood-2018-99-118631

Published: 2018

Journal Articles

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

Evangelos Terpos, MD PhD, Maria Roussou, MD, Ioannis Ntanasis-Stathopoulos, MD, Nikolaos Kanellias, MD, Despina Fotiou, MD, Dimitrios C. Ziogas, MD, Aristea-Maria Papanota, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Gavriatopoulou, MD, Efstathios Kastritis, MD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2018-99-113108

Published: 2018

Journal Articles

Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients

Federica Costa, MS, Marina Bolzoni, PhD, Rosanna Vescovini, PhD, Fabrizio Accardi, MD, Anna Benedetta Dalla Palma, MD, Federica De Luca, PhD, Valentina Marchica, MS, Denise Toscani, PhD, Emanuela Vicario, MS, Paola Storti, PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2018) 132 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2018-99-118200

Published: 2018

Journal Articles

Diffuse Medullary Hyperdensities of the Femora and Humeri on Whole-Body Low-Dose Computed Tomography Identify Diffuse MRI Pattern of Involvement and Correlate with Advanced Disease Stage in Patients with Multiple Myeloma

Vassilis Koutoulidis, Evangelos Terpos, MD PhD, Ioannis Ntanasis-Stathopoulos, Flora Zagouri, Ioanna Klapa, Andriani Boultadaki, Maria Gavriatopoulou, Sophia Fontara, Eftathios Kastritis, Meletios A. Dimopoulos, Lia A. Moulopoulos

Blood (2017) 130 (Supplement 1): 4404.

https://doi.org/10.1182/blood.V130.Suppl_1.4404.4404

Published: 2017

Journal Articles

Outpatient Stem Cell Mobilization with Low and Intermediate Dose Cyclophosphamide Is a Safe and Effective Procedure in Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplantation

Alessandra Pompa, Laura Paris, MD, Francesca Guidotti, MD, Valeria Ferla, MD, Monica Galli, MD PhD, Alessandro Rambaldi, MD Prof, Luca Baldini, Agostino Cortelezzi, Prof

Blood (2017) 130 (Supplement 1): 4476.

https://doi.org/10.1182/blood.V130.Suppl_1.4476.4476

Published: 2017

Journal Articles

Strong Immunoexpression of Dickkopf-1 Is Associated with Response to Bortezomib in Multiple Myeloma

Yong Won Choi, MD, Tae Hwan Kim, MD, Seong Hyun Jeong, MD, Jae Ho Han, MD, Joon Seong Park

Blood (2016) 128 (22): 3270.

https://doi.org/10.1182/blood.V128.22.3270.3270

Published: 2016

Journal Articles

EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability

Juraj Adamik, PhD, Rebecca Silbermann, MD, Konstantinos Lontos, MD, Peng Zhang, PhD, Quanhong Sun, Deborah Lynn Galson, PhD, G. David Roodman, MD PhD

Blood (2016) 128 (22): 3247.

https://doi.org/10.1182/blood.V128.22.3247.3247

Published: 2016

Journal Articles

18F-FDG-PET/CT and Osteolytic Bone Disease in Multiple Myeloma

Brian Østergaard, MD, Julie R. Mortensen, MD, Anne L Nielsen, MD, Jon T. Asmussen, MD, Oke Gerke, Statistician, Torben Plesner, Professor, Poul Flemming Høilund-Carlsen, MD Professor, Niels Abildgaard, MD Professor

Blood (2016) 128 (22): 5622.

https://doi.org/10.1182/blood.V128.22.5622.5622

Published: 2016

Journal Articles

Functional Geriatric Assessment (F-GA) in Multiple Myeloma Patients: Results from a Prospective Multicenter Study Group (DSMM) Trial and Changes from Baseline to Follow-up Assessment

Sophia Scheubeck, Sandra Maria Dold, M. Sc., Gabriele Ihorst, PhD, Alexander Zober, MD, Stefan J. Müller, Dipl.-Pharm., Christian Langer, MD, Wolfram Pönisch, Lars-Olof Mügge, MD, Stefan Knop, MD, Justus Duyster, MD, Martin Schumacher, PhD, Ralph M. Waesch, MD, Monika Engelhardt, MD

Blood (2016) 128 (22): 5627.

https://doi.org/10.1182/blood.V128.22.5627.5627

Published: 2016

Journal Articles

Outpatient Stem Cell Mobilization with Intermediate-Dose Cyclophosphamide Is a Safe and Effective Procedure

Alessandra Pompa, MD, Anna Ines Gregorini, MD, Francesca Guidotti, MD, Maria Cecilia Goldaniga, MD, Francesca Gaia Rossi, MD, Riccardo Marcolin, Luca Baldini, MD Prof, Agostino Cortelezzi, MD

Blood (2016) 128 (22): 5734.

https://doi.org/10.1182/blood.V128.22.5734.5734

Published: 2016

Journal Articles

Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group

Blood (2016) 128 (22): 4468.

https://doi.org/10.1182/blood.V128.22.4468.4468

Published: 2016

Journal Articles

MGUS with t(11;14) and t(14;16) in Different Cell Clones

Tanja Hinrichsen, Hanns-Georg Klein, MD, Burkhard Schmidt, MD

Blood (2016) 128 (22): 5604.

https://doi.org/10.1182/blood.V128.22.5604.5604

Published: 2016

Journal Articles

Regulation of Osteoblast Function in Myeloma Bone Disease By Semaphorin 4D

Attaya Suvannasankha, MD, Colin D Crean, Douglas R Tompkins, Jesus Delgado-Calle, PhD, Teresita M Bellido, PhD, G. David Roodman, MD PhD, John M Chirgwin, PhD

Blood (2016) 128 (22): 4439.

https://doi.org/10.1182/blood.V128.22.4439.4439

Published: 2016

Journal Articles

Circulating Adiponectin and Markers of Endothelial and Cardiovascular Dysfunction Correlate with Disease Burden in Newly Diagnosed Patients with Multiple Myeloma; Increase of Adiponectin after Bortezomib- and IMiD-Based Regimens

Evangelos Terpos, Ioannis Papassotiriou, Efstathios Kastritis, MD, Gerasimos-Petros Papassotiriou, Dimitrios Christoulas, Nikolaos Kanellias, Anna Komitopoulou, Evangelos Eleutherakis-Papaiakovou, Ioannis Panagiotidis, Maria Gavriatopoulou, Emilia Mantzou, Meletios A. Dimopoulos

Blood (2016) 128 (22): 4446.

https://doi.org/10.1182/blood.V128.22.4446.4446

Published: 2016

Journal Articles

Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial

Blood (2016) 128 (22): 992.

https://doi.org/10.1182/blood.V128.22.992.992

Published: 2016

NARROW

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

TBK1/Ikkε Inhibitor Amlx Blocks Multiple Myeloma Cell Growth in Vitro and In Vivo

Decreased Skeletal Health Negatively Impacts Quality of Life of People with Hemophilia

Uninvolved Immunoglobulin Suppression Determined By "Hevylite" ASSAY. Strongly Predicts Evolution of Smoldering Myeloma (SMM) to Symptomatic Multiple Myeloma (MM)

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients

Diffuse Medullary Hyperdensities of the Femora and Humeri on Whole-Body Low-Dose Computed Tomography Identify Diffuse MRI Pattern of Involvement and Correlate with Advanced Disease Stage in Patients with Multiple Myeloma

Outpatient Stem Cell Mobilization with Low and Intermediate Dose Cyclophosphamide Is a Safe and Effective Procedure in Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplantation

Strong Immunoexpression of Dickkopf-1 Is Associated with Response to Bortezomib in Multiple Myeloma

EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability

18F-FDG-PET/CT and Osteolytic Bone Disease in Multiple Myeloma

Functional Geriatric Assessment (F-GA) in Multiple Myeloma Patients: Results from a Prospective Multicenter Study Group (DSMM) Trial and Changes from Baseline to Follow-up Assessment

Outpatient Stem Cell Mobilization with Intermediate-Dose Cyclophosphamide Is a Safe and Effective Procedure

Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group

MGUS with t(11;14) and t(14;16) in Different Cell Clones

Regulation of Osteoblast Function in Myeloma Bone Disease By Semaphorin 4D

Circulating Adiponectin and Markers of Endothelial and Cardiovascular Dysfunction Correlate with Disease Burden in Newly Diagnosed Patients with Multiple Myeloma; Increase of Adiponectin after Bortezomib- and IMiD-Based Regimens

Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only